Compass Pathways may be the first to benefit from an accelerated approval process.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical ...

Compass Pathways stock surged Monday after President Donald Trump signed an executive order tied to psychedelic drugs.

Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive ...

COMPASS Pathways (CMPS) stock jumped 25% after Trump's executive order on psychedelic research. Positive Phase 3 data boosts ...

Compass Pathways (NASDAQ:CMPS) executives outlined the company’s latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami ...

It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the ...